Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Diseases
Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Disease
News Novartis abandons Fabhalta trial in lupus nephritis A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
